Objectives 1. Identify barriers to research engagement for patients who have undergone colectomy and pouch surgery for UC. 2. Develop and prioritize a patient-centered CER agenda to prevent and/or treat pouchitis and CLDP, unique, unfortunate, and rare diseases. 3. Identify, train, and empower a cohort of patients with or at-risk for pouchitis and CLDP to effectively partner in designing and conducting high-priority patient-centered CER.

To assess the effects of intervention on histologic disease activity following 12 weeks of treatment

1. Create a prospective cohort of well-phenotyped adult CD, UC and IBDU patients with serial clinical and patient-reported data collected throughout 12 months of Zymfentra (IFX -dyyb) therapy. 2. To determine clinical response and remission rates, course of stool calprotectin values and persistence of therapy with Zymfentra (IFX -dyyb) for induction and maintenance therapy. 3. Assess the correlation of various outcome measures in CD, UC or IBDU (short Crohn's disease activity index (sCDAI), Simple Clinical Colitis Activity Index (SCCAI), Urgency score, Fatigue,SIBDQ, PROMIS measures for depression, anxiety, and social satisfaction and work productivity and activity impairment. 4. Assess the effect of Zymfentra (IFX-dyyb) on patient reported fistula symptoms in patients with CD with pre-existing perianal fistulizing disease. 5. Assess persistence and need for dose escalation therapy of Zymfentra (IFX-dyyb). 6. Assessment of trough levels taken in the setting of standard of care before and after start of Zymfentra (IFX-dyyb).

Phase 2b Induction: To evaluate the efficacy of icotrokinra versus placebo in inducing clinical response Phase 3 Induction: To evaluate the efficacy of icotrokinra versus placebo in induction Phase 3 Maintenance: To evaluate the efficacy of icotrokinra versus placebo in maintenance

To create a biorepository for future research studies to better improve patient treatment in care for patients with liver cancer and liver diseases

What is the real-world effectiveness of etrasimod in adult patients ages ≥18 years and <65 years with moderately to severely active UC?

Assess the clinical response to treatment with mirikizumab among patients with chronic inflammatory conditions of the pouch using standardized outcome assessments.

To learn if one kind of treatment approach, either (1) endoscopic surveillance or (2) endoscopic eradication therapy, is better, the same, or worse for treating patients with Barrett's esophagus and low-grade dysplasia.

The purpose of this research study is to learn more about Barrett's Esophagus and esophageal cancer by collecting data and samples (blood and tissue) for a biorepository. A biorepository is a large bank of specimens and data that are stored indefinitely and may be shared with other researchers.

The study is designed to look at Crohn's disease over a period time, from before a surgery to 12 months after the surgery has taken place. The role bacteria in the gut plays in Crohn's disease (CD) is not well understood. Which particular microbes contribute to disease remain unknown. In CD, ~70% of patients will end up requiring surgery due to chronic unrelenting complications, and ~50% require additional surgery. We hope to identify key microbes at the time of surgery in stool and tissue and correlate it over time with data collected at timepoints after surgery. We will use this data with clinical information to determine if specific microbes are associated with disease recurrence.